Merck, Sharp & Dohme (MSD; NYSE: MRK) has unveiled plans to develop a multi-valent human papillomavirus (HPV) vaccine aimed at providing broader protection than the currently approved 9-valent Gardasil 9. This new candidate will include additional virus-like particles (VLPs) targeting HPV types that disproportionately affect populations in Africa and Asia, with clinical trials expected to commence in Q4 2024.
In conjunction with this initiative, MSD announced forthcoming comparative trials to assess the short- and long-term efficacy and immunogenicity of a single-dose regimen of Gardasil 9 versus the established triple-dose scheme. These studies will focus on recruiting males and females aged 16 to 26, set to begin in Q4 2024.- Flcube.com
